| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() DG DISPATCH - AACAP: Bupropion SR Effective In Treating Adult AD/HD By Lara Pullen Special to DG News CHICAGO, IL -- October 26, 1999 -- Despite the increased recognition of adult attention deficit/hyperactivity disorder (AD/HD), there are very few placebo-controlled clinical trials addressing its pharmacotherapy. A new study indicates that bupropion SR (sustained release) results in clinically and statistically significant improvement of AD/HD in adults.
At the 46th annual meeting of the American Academy of Child and Adolescent Psychiatry, Dr. Timothy E. Wilens, of Massachusetts General Hospital, in Boston, presented the results of a randomized, double-blind, placebo-controlled trial. This trial follows an open report that suggested the usefulness of bupropion SR in adults with AD/HD. The study comprised 40 adults (18 women/22 men) with a mean age of 38 years. Bupropion SR was initiated at 100 mg/day and titrated by 100 mg/day at weekly intervals to a target dose of 400 mg/day (200 mg twice daily). The results show bupropion SR treatment was associated with a significant reduction in AD/HD symptoms which exceeded placebo at the end of the six-week treatment period. Seventy-six percent of subjects on bupropion SR were judged under blind conditions to have a positive response to treatment. The mean dose of bupropion SR was 362 mg/day. The bulk of improvement in AD/HD symptoms occurred after week four, suggesting either a titration effect or delayed onset of action.
Related Link: bupropion SR (sustained release).
|